Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital

International Journal of Clinical Practice

Volumn 67, Issue 6, 2013, Pages 505-511

  Avkan Oguz, V ^a   Yapar, N ^a   Alp Cavus, S ^a   Demir Onder, K ^a   Aktas, E ^a   Gulay, Z ^a   Cakitr, N ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ACINETOBACTER; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC THERAPY; APPENDICITIS; ARTICLE; CELLULITIS; CHOLECYSTITIS; COMMUNITY ACQUIRED PNEUMONIA; COMPLICATED SKIN AND SOFT TISSUE INFECTION; DECUBITUS; DIABETIC FOOT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FOLLOW UP; FOURNIER GANGRENE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; NECROTIZING FASCIITIS; OBSERVATIONAL STUDY; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPERINFECTION; SURGICAL INFECTION; TREATMENT DURATION; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SUPERINFECTION; TREATMENT OUTCOME;

EID: 84878022695     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12070     Document Type: Article

References (23)

1. Pankey GA,. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80. (Pubitemid 41264122)
2. Metan G, Alp E, Yitlditz O, Perçin D, Aygen B, Sümerkan B,. Clinical experience with tigecycline in the treatment of carbepenem-resistant Acinetobacter infections. J Chemother 2010; 22: 110-4.
3. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu F,. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? J Chemother 2011; 23: 345-9.
4. Eser OK, Ergin A, Tunçkanat F, Hasçelik G,. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp. New Microbiol 2008; 31: 535-42.
5. Timurkaynak F, Arslan H, Azap OK, et al., In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients. Burns 2008; 34: 1033-6.
6. Akcam FZ, Kaya O, Basoglu N, Avsar K, Yayli G,. E-test minimum inhibitory concentrations for tigecycline against nosocomial Acinetobacter baumannii strains. J Chemother 2007; 19: 230-1. (Pubitemid 46697746)
7. Dinleyici EC, Yargic ZA, Bor O, Kiremitci A, Durmaz G,. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 55: 349-51.
8. Tekçe AY, Erbay A, Çabadak H, Yaǧcit S, Karabiber N, Şen S,. Pan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case report. Surg Infect (Larchmt) 2011; 12: 141-3.
9. Chandra A, Mangam S, Marzouk D,. A review of risk scoring systems utilised in patients undergoing gastrointestinal surgery. J Gastrointest Surg 2009; 13: 1529-38.
10. http://www.srga.org/eucastwt/MICTAB/RD/tigecyclinerationale1.0.pdf (accessed July 2012).
11. Stevens DL, Bisno AL, Chambers HF, et al., Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 137-406.
12. Solomkin JS, Mazuski JE, Bradley JS, et al., Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis 2010; 50: 133-64.
13. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 suppl. 5: S354-67. (Pubitemid 41170382)
14. Fomin P, Koalov S, Cooper A, et al., The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections-the European experience. J Chemother 2008; 20 (Supp. 1): 12-9.
15. Passarell JA, Meagher AK, Liolios K, et al., Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agent Chemother 2008; 52: 204-10.
16. Secondo G, Vassallo F, Solari N, et al., Empirical first-line treatment with tigecycline for febril episodes following abdominal surgery in cancer patients. Int J Antimicrob Agents 2010; 36: 462-6.
17. Dryden MS,. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65: 35-44.
18. Teras J, Gardovskis J, Vaasna T, et al., 305 Study Group. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections-a European perspective. J Chemother 2008; 20: 20-7.
19. Allen DM, Hartman BJ,. Acinetobacter species. In:, Mandell GL, Bennett JE, Dolin R, (eds). Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7th edn. Churchill, Livingstone: Philadelphia, 2010: 2881-6.
20. Tacconelli E, De Angelis G, Cataldo MA, et al., Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agent Chemother 2009; 53: 4264-9.
21. Sacchidanand S, Penn RL, Embil JM, et al., Efficacy and safety of tigecycline monotherapy compared with vancomycine plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61. (Pubitemid 41196869)
22. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E,. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-70. (Pubitemid 351263497)
23. Garcia-Cabrera E, Jimenez-Mejias ME, Navarro MVG, et al., Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010; 29: 867-71.